Get started
Author

Andrea Local

Observed name: A. Local
ORCID: 0000-0003-2963-0607
Observed ORCID: 0000-0003-2963-0607
OpenAlex ID: A5014765656
Identification of H3K4me1-associated proteins at mammalian enhancers
2017 · Andrea Local, Hui Huang, et al. · Nature Genetics · 234
Histone H3 lysine 4 monomethylation modulates long-range chromatin interactions at enhancers
2018 · Jian Yan, Shi-An A Chen, et al. · Cell Research · 198
PDF
APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
2018 · Andrea Local, Hongying Zhang, et al. · Molecular Cancer Therapeutics · 83
PDF
Erratum: Histone H3 lysine 4 monomethylation modulates long-range chromatin interactions at enhancers
2018 · Jian Yan, Shi-An A Chen, et al. · Cell Research · 30
PDF
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
2018 · Cheng-Yu Tsai, Si Sun, et al. · Molecular Cancer Therapeutics · 22
PDF
Identification and Expression of Cotton (Gossypium hirsutum L.) Plastidial Carbonic Anhydrase
1999 · Chau V. Hoang, Heath G. Wessler, et al. · Plant and Cell Physiology · 14
Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivo
2021 · Steven A. Saenz, Andrea Local, et al. · PLoS ONE · 12
PDF
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
2022 · William G. Rice, Stephen B. Howell, et al. · Molecular Cancer Therapeutics · 11
Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia
2016 · Hongying Zhang, Andrea Local, et al. · Blood · 5
Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro
2018 · Hongying Zhang, Andrea Local, et al. · Cancer Research · 4
CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells
2018 · Hongying Zhang, Andrea Local, et al. · Blood · 3
CG′806, a First-in-Class FLT3/BTK Inhibitor, Exerts Superior Potency against AML Cells Harboring ITD, TKD and Gatekeeper Mutated FLT3 or Wild-Type FLT3
2017 · Weiguo Zhang, Hongying Zhang, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies
2016 · Ram S. Upadhayaya, Raghava Reddy Kethiri, et al. · Blood · 3
Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes
2017 · Stephen E. Kurtz, Beth Wilmot, et al. · Clinical Cancer Research · 2
APTO-253 Interaction with G-Quadruplex DNA Is Linked to Inhibition of c-Myc Expression, Induction of DNA Damage, and Generation of Synthetic Lethality in Cells with BRCA1/2 Impairment
2017 · Andrea Local, Hongying Zhang, et al. · Blood · 2
CG '806, a First-in-Class Non-Covalent Pan-FLT3/BTK Inhibitor, Exerts Superior Potency Against B-Cell Malignant Cells
2017 · Hongying Zhang, Andrea Local, et al. · Blood · 2
Abstract 25: CG′806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3
2017 · Weiguo Zhang, Hongying Zhang, et al. · Clinical Cancer Research · 1
CG '806, a Highly Potent First-in-Class Pan-FLT3/BTK Inhibitor, Targets Multiple Clusters of Kinases Operative in Diverse Subtypes of Acute Myeloid Leukemia
2017 · Hongying Zhang, Andrea Local, et al. · Blood · 1
Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies
2015 · William G. Rice, Jeff Lightfoot, et al. · Blood · 1
Figure S3 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
2023 · Cheng-Yu Tsai, Si Sun, et al.
PDF
Table S3 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
2023 · Cheng-Yu Tsai, Si Sun, et al.
Figure S1 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
2023 · Cheng-Yu Tsai, Si Sun, et al.
PDF
Figure S2 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
2023 · Cheng-Yu Tsai, Si Sun, et al.
PDF
Table S2 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
2023 · Cheng-Yu Tsai, Si Sun, et al.
PDF
Table S1 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
2023 · Cheng-Yu Tsai, Si Sun, et al.
PDF
Works count: 56
Citation count: 631
H-index: 8
I10-index: 8
Year
Topic
Type